Retatrutide and tirzepatide are two of the most closely watched incretin-based peptides in metabolic research. On paper they look similar, both are once-weekly, albumin-bound peptides that activate the GIP receptor, but their designs diverge in one decisive way: tirzepatide is a dual GIP/GLP-1 receptor agonist, while retatrutide adds a third receptor arm, glucagon, making it a triple agonist. This article compares what the published trials actually reported for each compound, mechanism, weight-loss and glycemic data, dosing and tolerability, and where the honest limits of any “retatrutide vs tirzepatide” comparison lie.
Two incretin peptides, two different designs
Both molecules descend from the same line of Eli Lilly research and share a structural trick: a C20 fatty-diacid chain that binds reversibly to plasma albumin, slowing renal clearance and stretching the half-life to roughly one week [4][8]. That is why both are dosed once weekly by subcutaneous injection. The difference is how many receptors a single molecule engages.
The shared GIP/GLP-1 backbone
Tirzepatide (research code LY3298176) is a 39-amino-acid peptide that activates the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Its pharmacology is deliberately imbalanced: it binds GIPR with roughly native-GIP affinity but acts as a partial agonist at GLP-1R, and it biases signaling toward cAMP over β-arrestin recruitment [8][9]. Retatrutide (LY3437943) keeps this GIP/GLP-1 backbone, the two arms that drive glucose-dependent insulin secretion and central appetite suppression, but is tuned with its own asymmetric potency profile, highest at GIPR [4].
The third arm: glucagon
What sets retatrutide apart is agonism at the glucagon receptor (GCGR). Glucagon is best known for raising blood glucose, but sustained receptor stimulation also increases energy expenditure and hepatic fat oxidation. The triple-agonist idea is to pair the appetite- and glucose-lowering effects of GIP/GLP-1 with an added energy-expenditure component from glucagon, while the incretin arms offset glucagon’s tendency to raise glucose [4]. In short: tirzepatide leans on two levers, retatrutide on three.
What the third receptor arm is meant to add
The practical bet behind the triple design is that glucagon-driven energy expenditure and hepatic fat oxidation stack on top of the appetite suppression that GIP/GLP-1 already provide, potentially pushing both weight loss and liver-fat reduction beyond what a dual agonist reaches [3][4]. The catch is balance: too much glucagon activity would raise blood glucose, so the molecule’s incretin arms have to counter it. Whether that added arm translates into a durable clinical advantage over tirzepatide is still a phase 2 hypothesis rather than a settled result, which is exactly why the cross-trial caution further down matters.
Weight-loss data: what the trials reported
This is the headline question behind most “retatrutide vs tirzepatide” searches, so an apples-to-oranges warning belongs up front (more on that below). Here is what each program actually published.
In the phase 2 obesity trial of retatrutide (338 adults without diabetes, 48 weeks), mean weight change at the highest dose reached −24.2% at 12 mg versus −2.1% on placebo; the 8 mg group reached −22.8% and the 4 mg group −17.1%. At the top dose, roughly 93% of participants lost at least 10% and about 83% at least 15% of body weight [1]. Notably, the weight curve had not clearly plateaued by week 48, suggesting the ceiling was not yet reached.
For tirzepatide, the key phase 3 SURMOUNT-1 obesity trial (2,539 adults without diabetes, 72 weeks) reported mean weight reductions of −15.0%, −19.5% and −20.9% at 5, 10 and 15 mg respectively, versus −3.1% on placebo [6]. These are among the largest reductions ever reported for an approved-class agent in a trial of that size and duration.
| Feature | Retatrutide (LY3437943) | Tirzepatide (LY3298176) |
|---|---|---|
| Receptor targets | GIP + GLP-1 + glucagon (triple) | GIP + GLP-1 (dual) |
| Most advanced weight-loss data | Phase 2, 48 weeks, n=338 [1] | Phase 3 (SURMOUNT-1), 72 weeks, n=2,539 [6] |
| Top-dose mean weight change | −24.2% (12 mg) [1] | −20.9% (15 mg) [6] |
| Placebo weight change | −2.1% [1] | −3.1% [6] |
| Top HbA1c reduction (T2D) | up to −2.02% (phase 2) [2] | up to −2.30% (SURPASS-2) [7] |
| Approx. half-life | ~6 days [4][5] | ~5 days [8] |
| Route / frequency | Subcutaneous, once weekly | Subcutaneous, once weekly |
| Trial maturity | Phase 3 ongoing (investigational) | Phase 3 completed; approved medicine in several markets |
Glycemic control in type 2 diabetes
A separate phase 2 trial of retatrutide in type 2 diabetes (281 adults, 36 weeks) reported HbA1c reductions at week 24 of up to −2.02% at 12 mg, versus −0.01% on placebo and −1.41% on the GLP-1 agonist dulaglutide; body weight at week 36 fell to about −16.9% at the top dose [2].
Tirzepatide was tested head-to-head against semaglutide 1 mg in SURPASS-2 (1,879 adults with type 2 diabetes): HbA1c reductions reached −2.30%, and weight loss exceeded semaglutide at every dose [7]. It is one of the few incretin trials with an active comparator rather than placebo alone.
Beyond weight: liver fat
In a phase 2a trial of retatrutide in metabolic dysfunction-associated steatotic liver disease (98 participants with hepatic fat content ≥10%), liver-fat reduction at week 24 ranged from −42.9% to −82.4% versus +0.3% on placebo, with normal liver fat (<5%) reached in a large share of the higher-dose groups [3]. Tirzepatide has its own hepatic-fat and metabolic data, but the glucagon arm of the triple mechanism is specifically hypothesized to drive hepatic lipid oxidation.
Dosing in the studies
Both programs used weekly subcutaneous injection with stepwise titration over several weeks to improve gastrointestinal tolerability. Retatrutide’s phase 2 titrated to targets up to 12 mg [1][5]; tirzepatide’s studied maintenance doses were 5, 10 and 15 mg [6]. The full escalation schedules are laid out in the published protocols; we do not reproduce them here.
Tolerability
Across both, the dominant adverse events were gastrointestinal, nausea, diarrhea, vomiting, constipation, mostly mild-to-moderate and dose-dependent, more frequent at higher doses and faster titration [1][2][6]. Retatrutide also showed dose-dependent heart-rate increases in phase 2; longer, larger phase 3 data are needed to fully characterize its profile.
Why this is not a true head-to-head
No randomized trial has compared retatrutide directly against tirzepatide. Every number above comes from separate studies with different populations, durations and phases: retatrutide’s −24.2% is a phase 2, 48-week, 338-person result, while tirzepatide’s −20.9% is a phase 3, 72-week, 2,539-person result [1][6]. Cross-trial comparison cannot account for these differences, and retatrutide’s phase 3 program is still ongoing while tirzepatide has completed phase 3 and is an approved medicine in several markets. Treat the side-by-side numbers as descriptive, not as proof that one molecule outperforms the other. A fair comparison would require one trial that randomizes both molecules under an identical protocol, the same doses, duration, titration and population; until such a study is run, retatrutide’s apparent edge at its top dose is suggestive, not established.
Reference material and where to read more
For the full receptor pharmacology, trial-by-trial breakdown and pharmacokinetics of each compound, see our scientific monographs: retatrutide monograph and tirzepatide monograph. The corresponding research-grade reference items are Retatrutide and Tirzepatide, both supplied as lyophilized powder with HPLC (high-performance liquid chromatography, a purity-testing method) purity documentation.
Research-use-only note
This article is compiled from publicly available peer-reviewed publications and clinical-trial reports and is provided for reference and informational purposes only. It is not medical advice and not a recommendation for use. Retatrutide is an investigational compound; both peptides referenced here are supplied strictly for laboratory research purposes only, not for human or animal consumption, and not for diagnostic or therapeutic use. All doses and results described above come from controlled research settings and must not be interpreted as instructions.
The full list of sources with links, is in the monographs: Retatrutide, Tirzepatide.
